AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania (Penn) focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation.